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Predictors of the progression of renal insufficiency in patients with
insulin-dependent diabetes and overt diabetic nephropathy. We designed
a prospective, double-blind controlled trial to determine predictors of loss
of renal function in patients with insulin dependent diabetes and estab-
lished nephropathy. A total of 409 insulin-dependent diabetic patients
with established nephropathy enrolled in a trial on the effect of Captopril
on the rate of progression of renal disease. Baseline demographic, clinical
(history and physical) and laboratory parameters were analyzed as risk
factors for time to progression. Dichotomous characteristics were com-
pared by Fisher's exact test and continuous characteristics with the
Wilcoxon rank-sum test. Univariate proportional hazards regression anal-
ysis was used to estimate relative risk of nephropathy progression, and
bivariate proportional hazard regression to identify interactions with the
treatment group assignment. Multivariate proportional hazard regression
was employed to determine which characteristics were independent risk
factors. We found that a number of demographic and clinical character-
istics were significantly associated with nephropathy progression even
after adjustment for treatment group. However, after multivariate analy-
sis, the risk factors that independently predicted progression were onset of
IDDM later in life, parental diagnosis of IDDM, the presence of edema,
increased mean arterial pressure, and an abnormal electrocardiogram.
Likewise, a number of laboratory characteristics were also predictive of
nephropathy progression. A low hematocrit, high blood sugar, and higher
protein excretion predicted nephropathy progression as did a higher
serum creatinine, particularly in the face of a normal serum albumin. In
conclusion, this study identifies a number of clinical and laboratory risk
factors that can predict which patients with insulin-dependent diabetes
with established nephropathy are more likely to sustain a clinically
important decrease in renal function over a median follow-up of three
years.
Diabetic nephropathy is the single most common cause of renal
failure leading to enrollment in the Medicare End-Stage Renal
Program [1, 2]. A substantial subset of approximately 35 to 40% of
insulin dependent diabetics develop nephropathy [3]. Once dia-
betic nephropathy is established the rate of loss of renal function
appears to be extremely variable [4]. There have been several
studies that have examined the factors that impact on the risk for
the development of nephropathy in diabetic populations; as such,
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microalbuminuria and hypertension are now well established
predictors [5, 6]. In contrast, only few studies have examined
factors that may or may not impact the rate at which renal
functional loss ensues once nephropathy is well established by the
presence of proteinuria. In small studies, race [7, 8], hypercholes-
terolemia [9], the degree of proteinuria [10], mean arterial
pressure [11, 12], diuretic use [13] as well as the levels of
hemoglobin A1C [14], angiotensin II and aldosterone [151 have all
been identified as potential predictors of progression in such a
population. However, there is no large scale study that simulta-
neously has examined several potential factors in the same
population. The clinical trial of angiotensin converting enzyme
inhibition with Captopril in 409 patients with insulin-dependent
diabetes and diabetic nephropathy demonstrated that assignment
to Captopril treatment reduced the risk of progressive renal
disease [16]. This patient cohort offers a unique database from
which potential predictors of progressive loss of renal function in
patients with insulin-dependent diabetes can be identified. In the
present study, we systematically analyzed the impact of a large
number of baseline characteristics on the loss of renal function in
this cohort of subjects with established diabetic nephropathy.
Methods
The study was a prospective, double-blind, randomized clinical
trial performed in 30 clinical centers [16]. The study protocol was
approved by the institutional review board at each center, and all
patients gave written informed consent.
Entty and exclusion criteria
Patients 18 to 49 years of age were eligible if they had
insulin-dependent diabetes mellitus for at least seven years, with
an onset before the age of 30 years, and had diabetic retinopathy,
urinary protein excretion of  500 mg per 24 hours, and a serum
creatinine concentration of < 2.5 mg per deciliter (220 jimol per
liter). All patients satis'ing these criteria were eligible for the
study, regardless of previous blood-pressure status or a previous
need for antihypcrtensive medication. Patients who were receiv-
ing angiotensin-converting-enzyme inhibitors or calcium channel
antagonists were eligible provided their blood pressure could be
maintained within the blood-pressure goals required by the trial
without these drugs. Therapy with an angiotensin-converting-
enzyme inhibitor, other than the coded medication, and calcium
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channel antagonists were not allowed during the trial. Patients
were excluded for the following reasons: pregnancy, a dietary
evaluation that indicated marked departure from standard dietary
recommendations, white-cell count below 2500 per cubic millime-
ter, congestive heart failure (New York Heart Association class
III or worse), and a serum potassium concentration of  6 mmol
per liter.
Eligible patients were stratified according to center and ran-
domly assigned to a group according to a standard urn design.
Those assigned to the Captopril group received a dose of 25 mg
three times daily, and those assigned to the control group received
identical-appearing placebo tablets three times daily.
The patients' diabetes was managed in accord with their
historical treatment schedule. Diabetes control was monitored by
measurements of glycosylated hemoglobin. After randomization,
the patients were seen at two weeks, at one month, and every
three months thereafter until they died, required dialysis, or
underwent renal transplantation. Compliance in taking the coded
medications was determined by the nurse coordinators with the
pill-count method. The patients' vital status, need for dialysis, and
need for transplantation were monitored until September 30,
1992. Glycosylated hemoglobin, serum creatinine, and 24-hour
urinary excretion of creatinine, protein, and urea were measured
by the central laboratory at each visit according to standard
methods.
Outcomes
The primary study outcome was a doubling of the baseline
serum creatinine concentration to at least 2.0 mg per deciliter
(177 jmol per liter), confirmed by the central laboratory. Second-
ary analyses included the length of time to the combined end
points of death, dialysis, and transplantation and changes in renal
function, assessed in terms of the serum creatinine concentration,
24-hour creatinine clearance, and urinary protein excretion. Other
reasons for discontinuing the coded medication were defined for
patients whose blood pressure could not be maintained within the
limits dictated by the study and those with persistent hyperkale-
mia (potassium level exceeding 6 mmol per liter), adverse drug
effects, pregnancy, or intercurrent illness.
Statistical analysis
Statistical Analysis System software was used for all data
management and analysis [17]. Risk factors for time to progres-
sion of nephropathy (that is, doubling of baseline serum creati-
nine concentration to at least 2.0 mg per deciliter) included
baseline demographic, clinical (history and physical) and labora-
tory characteristics. Dichotomous baseline characteristics of the
nephropathy progression groups were compared with Fisher's
exact test [18]; continuous baseline characteristics were compared
with Wilcoxon rank-sum tests [19]. For each of these baseline
characteristics, a univariate proportional hazards regression
model was used to estimate the relative risk (that is, hazard rate
ratio) of nephropathy progression and corresponding 95% confi-
dence interval; the Wald criterion was used to assess significance
of association (all reported P values are two-sided) [20]. To
improve the skewness of the baseline distributions of serum
glucose and 24-hour urine total protein, values were log-trans-
formed for the proportional hazards regression analysis.
Bivariate proportional hazards regression was used to identify
interactions between the treatment group assignment (Captopril
or placebo) and each of the baseline characteristics; the Wald
criterion was used to assess significance of the treatment group by
baseline covariate interaction. The regression models were hier-
archical such that whenever an interaction term was included in
the model, related lower-order terms were retained regardless of
their statistical significance. Multivariate proportional hazards
regression analysis was used to simultaneously consider the effects
of the treatment group assignment and the baseline demographic,
clinical and laboratory characteristics in predicting time to the
progression of nephropathy. Separately for the demographic and
clinical characteristics, and for the laboratory characteristics, the
full regression model was analyzed to develop a reduced model by
backward elimination, a sequential model fitting process in which
nonsignificant predictors are removed from the model and coef-
ficients for the remaining predictors are recomputed.
Results
As previously reported, between December 1987 and October
1990, 409 insulin-dependent diabetic mellitus (IDDM) partici-
pants with nephropathy were randomized to either Captopril
treatment [207] or placebo [202] [16]. The randomized partici-
pants were primarily Caucasian, which reflects the distribution of
IDDM by race in the population. Only 32 African-American
participants were in the trial. The majority of participants during
baseline were edema free. Over 70% of participants had serum
creatinine < 1.5 at baseline. During a median follow-up period of
three years (range 1.8 to 4.8), a total of 68 doubling of serum
creatinine events were observed: 25 in the Captopril group and 43
in the placebo group. The risk of creatinine doubling among
participants assigned to Captopril treatment to the risk of creat-
mine doubling among participants assigned to placebo treatment
was reduced by 48.5% [16].
Demographic and clinical risk factors of nephropathy progression
Table 1 presents the key baseline demographic, history and
physical examination characteristics in the IDDM participants
with nephropathy based on progression (defined by doubling of
baseline serum creatinine concentration to at least 2 mgldl during
the follow-up period). Increasing age at randomization, African-
American race, onset of IDDM later in life, a lower percent of life
with IDDM, and a parent diagnosed with diabetes were associated
with nephropathy progression during a median follow-up period
of three years. For the baseline physical examination parameters,
progression of nephropathy was associated with presence of
peripheral edema, hypertension, and increased mean arterial
pressure. Also, an abnormal EKG increased the risk of progres-
sion during the follow-up period. Among numerous factors that
did not significantly impact progression, were gender and the
presence or absence of a sibling with either diabetes alone or
diabetic renal disease.
Proportional hazards regression analysis was used to predict
nephropathy progression during the follow-up period using each
of the baseline characteristics summarized in Table 1 with adjust-
ment for treatment group assignment. As assignment to Captopril
treatment itself significantly decreased the progression of renal
disease, an analysis of the interaction between treatment group
and the listed demographics and clinical characteristics had to be
undertaken. There were no significant (P = > 0.20) interactions
between the treatment group assignment and any of the baseline
demographic and clinical characteristics. Thus, the relative risk of
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Characteristics
Number of participants
Assigned to Captopril
treatment %
Demographics
Age years
African-American race %
History of diabetes
Age at onset of IDDM years
Life with IDDM %
Parental diagnosis of
diabetes %
Physical examination
Peripheral edema %
Mean arterial pressure
mm Hga
Hypertension %h
Abnormal EKO report %C
Plusminus values are means SD. For categorical variables the P values
were based on Fisher's exact test. The P values for continuous variables
were based on the Wilcoxon test.
a Blood pressure was measured in seated, resting patients during an
office visitbHypertension was defined as a systolic pressure above 140 mm Hg, a
diastolic blood pressure above 90 mm Hg, or use of antihypertensive
medication (including diuretics)
Based on a total of 407 baseline EKG reports
nephropathy progression for each demographic and clinical char-
acteristic are similar in the Captopril and placebo treated groups.
As shown in Figure 1, after adjustment for treatment group
assignment, each of the baseline demographic and clinical char-
acteristics listed in Table I remained significant (P < 0.05)
predictors of time to nephropathy progression. The African-
Americans had a 3.5-fold increase in risk of nephropathy progres-
sion compared to non-African-Americans (95% confidence inter-
val, 1.8 to 6.5). Prominent history and physical examination risk
factors included age at onset of IDDM, peripheral edema and
mean arterial pressure. The treatment-adjusted relative risks of
nephropathy progression were: 1.4 per five years increase in age at
IDDM onset; 2.8 for subjects with peripheral edema; and 1.2 per
every 5 mm Hg increase in mean arterial pressure.
The demographic and clinical characteristics listed in Table I
were analyzed simultaneously to determine which characteristics
were independent risk factors for nephropathy progression ad-
justed for treatment group assignment. As shown in Table 2 by
multivariate analysis, some of the demographic and clinical base-
line characteristics remained as significant (P < 0.01) independent
risk factors of nephropathy progression. These include age of
onset of IDDM, parental diagnosis of diabetes, peripheral edema,
mean arterial pressure, and an abnormal EKG. In this analysis,
race no longer is an independent predictor of progression. This is
a consequence of the fact that the above-listed risk factors
themselves are more prominent in the African-American patients
and thereby eliminate race as an independent risk factor. The
most prominent risk factor was the presence of edema (adjusted
relative risk = 2.21; 95% confidence interval, 1.35 to 3.62). On the
other hand, age at randomization, percent of life with IDDM, and
Laboratory risk factors of nephropa thy progression
Table 3 presents the baseline laboratory measurements in those
who did and did not double their serum ereatinine during the
follow-up period. Participants who progressed had significantly
higher glycosylated hemoglobin, serum creatinine, cholesterol,
glucose, uric acid, and 24-hour urine total protein excretion. Low
levels of blood hematocrit, serum albumin, 24-hour urine urea
nitrogen, and renal clearance of either ereatinine or iothalamate
were associated with progression of nephropathy. There were no
significant (P  0.10) interactions between the treatment group
assignment and each of the baseline laboratory measurements
except for serum creatinine (P = 0.024). As shown in Figure 2,
after adjustment for treatment group assignment, each of the
baseline laboratory measurements were significant (P < 0.05)
predictors of time to nephropathy progression. Because serum
creatinine interacted with the treatment group assignment, the
relative risk of progression was estimated within each treatment
group. For participants assigned to placebo treatment, the risk of
nephropathy progression increased by 2.2 for each 0.25 mgldl
increase in serum creatinine. Similarly, the risk of nephropathy
progression increased by 1.6 for each 0.25 mg/dl increase in serum
creatinine for participants treated with Captopril.
The laboratory measurements listed in Table 3 were analyzed
simultaneously to determine which measurements were indepen-
dent risk factors of nephropathy progression adjusted for the
treatment group assignment (Table 4). As shown in this table, the
independent laboratory risk factors of nephropathy progression
were blood hematocrit, glucose, serum creatinine, and 24-hour
urine protein excretion. The risk of nephropathy progression
decreased with increasing blood hematocrit (adjusted relative
risk = 0.73 per increase of 4%). Likewise, risk of nephropathy
progression increased as the baseline serum creatinine increased.
Since there was a strong interaction between serum creatinine and
albumin the risk was calculated at two levels of serum albumin.
The risk was particularly marked at albumin of 4.0 gldl (1.79 per
increase of 0.25 mg/dl with 95% confidence intervals of 1.45 to
2.20). An increase in total protein excretion is also a strong
predictor, 2.00 (1.25 to 3.20) per fivefold increase in glday. It is
also of interest that Captopril treatment reduced the risk of
progressive renal insufficiency to an even greater extent (62% risk
reduction) than it did without adjustment for the laboratory
measurements listed in Table 4 (48.5%) [16].
Table 1. Baseline demographic and clinical characteristics predictive of
nephropathy progression during a median follow-up of three years
(range 1.8 to 4.8)
Doubling of serum creatinine
hypertension at baseline when simultaneously adjusted for the
other demographic and clinical factors listed in Table 2 proved
______
not to he the independent predictors of progression (P> 0.01).
All of the two-way interactions among the risk factors included in
Yes No P value the demographic and clinical characteristics model presented in
(8 341 Table 2 were nonsignificant (P > 0.01).
36 8 53 4 0016 Since baseline renal function is a potent predictor factor of
progression (vide infra, Table 3), we also analyzed the demo-
graphic and clinical baseline characteristics with baseline serum
36.5 6.80 34.1 7.71 (1.014 creatinine. After adjusting for renal function, the mean arterial
17.6 5.9 0.002 pressure and the abnormal EKG no longer are independent
(1.002 predictors. The others, including assignment to Captopril, age of
0.009 onset of IDDM, parental diagnosis of diabetes and peripheral
0.023 edema remained significant independent risk factors of creatinine
doubling.
15.8 8.46
58.3 17.5
38.2
12.4 6.89
64.5 15.9
24.0
48.5 23.2 <0.001
109 12.8 102 11.9 <0.001
85.3
35.3
73.3 0.044
18.0 0.003
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Demographic:
Age (5 years)
African American race
History of diabetes
Age at onset (5 years)
Percent of life with IDDM (10%)
Parental diagnosis of diabetes
Physical examination:
Peripheral edema
Hypertension
Discussion
1.0
Relative risk
The decline in renal function in patients with insulin-dependent
diabetes and established diabetic nephropathy can vary widely [4].
Being able to predict the subset of patients who will have a more
rapid decline in renal function and targeting them for specific
interventions is important. A variety of baseline characteristics
were identified that predicted progression of renal disease in the
patients with insulin-dependent diabetes and established diabetic
nephropathy. Among the demographic characteristics, an increase
in age and African-American race were such predictors. A later
onset of diabetes, a shorter percent of life with IDDM, a parental
(but not sibling) diagnosis of diabetes, and hypertension were
likewise predictors of progression. The longer percent of life with
TDDM in those who did not double their serum creatinine (64.5%
vs. 58.3%) in those that did may relate to the younger age of onset
of disease in this group (12.4 years) versus those that progressed
(15.8 years), since it appears that the time to complications is
better defined at puberty rather than onset of diabetesperse [211.
Also, the presence of edema, a high mean arterial pressure and a
report of an abnormal EKG also imparted a worse prognosis.
When adjusted for baseline renal function these latter two
Fig. 1. Risk of nephropathy progression
(doubling of serum creatinine) for each baseline
demographic or clinical characteristic corrected
for treatment group assignment (Captopril or
placebo) based on proportional hazards regression
analysis. The relative risk (dot) and
corresponding 95% confidence interval
(horizontal line) associated with each baseline
risk factor (or specified increase) are plotted on
a natural logarithm scale. A dot to the left of
the vertical line suggests a reduction in the risk
of nephropathy progression for the index
characteristic, while a dot to the right indicates
an increased risk of progression.
parameters are not independent factors. Among laboratory data,
a lower hematocrit, albumin, urea nitrogen excretion, creatinine
and an iothalamate clearance also were associated with progres-
sion as were a higher glycosylated hemoglobin, serum creatinine,
cholesterol, glucose, uric acid, and urinary protein excretion.
Progression of diabetic nephropathy is a multifactorial process.
The interrelationship between many risk factors often confounds
any attempt to assess the importance of individual risk factors. In
examining the baseline demographic variables, few African-
Americans were enrolled in this trial in part reflecting the greater
prevalence of NIDDM rather than IDDM in this population [7].
African-American race did not remain as an independent risk
factor for progressive renal disease since the African-Americans
enrolled had a higher mean arterial pressure, peripheral edema
and abnormal EKGs. In practical terms, if these other risk factors
are more prevalent in the IDDM African-American population as
a whole, then African-Americans presenting for medical care of
diabetic kidney disease will be more likely to have a rapid
progression of renal disease.
Gender did not predict progression in these patients. This is in
contrast to reports of a slower rate of progression of renal disease
Mean arterial pressure (5 mm Hg)
Abnormal EKG report
0.1 10
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Baseline risk factor
Assigned to Captopril treatment 0.54 (0.33 to 0.89)
Histoiy
Age at onset of IDDM 1.24 (1.07 to 1.44)
(per increase of 5 years)
Parental diagnosis of diabetes 1.69 (1.01 to 2.81)
Physical examination
Peripheral edema 2.21 (1.35 to 3.62)
Mean arterial pressure 1.19 (1.08 to 1.31)
(per increase of 5 mm Hg)
Abnormal EKG report 2.17 (1.30 to 3.61)
in women with polycystic kidney disease [22], IgA nephropathy
[23], and membranous glomerulonephritis [24]. In the Modifica-
tion of Diet and Renal Disease Study, 840 subjects with chronic
renal disease due to causes other than IDDM were enrolled.
Females had a slower rate of decline of renal function [251. Taken
together, it appears that in non-diabetic kidney disease gender
appears to be predictive of renal outcome. In contrast in the
present study, in which half of the subjects were females, no
protective effect of female gender was demonstrated. It is of
interest that in the Framingham Study, young hypertensive
women had less cardiovascular and cerebrovascular risk than
men. However, as in the present trial, this was not the case for
men and women with diabetes and hypertension who had equal
cardiovascular and cerebrovascular risk [26]. It is thus possible
that the presence of diabetes itself overcomes any potential
benefits of female gender in protecting renal function.
Hypertension has been identified as an important risk factor
that accelerates the progressive decline in kidney function in
diabetic nephropathy [15, 27]. Although the initial reports of
hypertension as a poor prognostic factor were in relatively small
groups of patients, in a recent cohort of 131 patients with
insulin-dependent and non-insulin diabetes a significant and
progressive increase in serum creatinine in individuals whose
systolic blood pressure remained elevated above 140 mm Hg while
on therapy was documented [28]. It was concluded on the basis of
this initial analysis of the data that persistent elevation of the
blood pressure added significantly to the progressive renal dam-
age. The group with higher blood pressures had significantly faster
rates of rise in their serum creatinine. In addition to hypertension
marking this group for a more rapid decline of renal function,
higher angiotensin II and aldosterone levels were also associated
with a faster rate of decline in renal function [281. Also, multiple
studies in patients with IDDM and established nephropathy have
demonstrated that lowering elevated blood pressures lead to a
slower rate of decline of renal function [29, 30]. En the present
analysis, it was found that higher mean arterial blood pressures at
baseline were associated with an increased risk of progressive
renal insufficiency during the follow-up period. The presence or
absence of hypertension itself at baseline was a significant predic-
tor of progression, but not independently when mean arterial
Yes
Number of participants 68
Assigned to Captopril 36.8
treatment %
Blood
Hematocrit % 35.6 4.89
Glycosylated hemoglobin % 12.7 3.73
Serum
Creatinine mg/dia 1.65 0.45
Albumin gidi 3.36 0.48
Cholesterol mg/di 275 75
Glucose mg/di 264 155
Uric acid mgidi 6.31 1.63
24-Hour urinea
Total protein giday 4.99 3.36
Urea nitrogen giday 9.43 4.31
Renal clearance
24-Hour creatinine 57.4 27.6
mI/mini]. 73 m2
4-Period lothalamate 51.4 22.2
mi/mini!. 73 m2
Plus minus values are means SD. Each laboratory characteristic had
400 or more baseline determinations except for 4-period lothalamate
clearance which had 396 baseline determinations. For categorical vari-
ables the P values were based on Fisher's exact test. The P value for
continuous variables were based in Wilcoxon test.
Measured by the central laboratory; local laboratory determination for
other characteristics
pressure at baseline was taken into account. A relatively small
increase in mean arterial pressure (5 mm Hg) was associated with
significant increases in the risk of doubling of serum creatinine.
Also, the mean arterial pressure in the group who doubled their
serum creatinine during follow-up was relatively low at 109 mm
Hg. A similar effect of higher arterial blood pressure as a risk for
progression is also found in non-diabetic renal disease [31]. It is of
interest that in our study the average mean arterial pressure at
baseline in the group who did not double their serum creatinine
was 7 mm Hg lower at 102 mm Hg. Blood pressures that on
average were only slightly above current JNC-V recommenda-
tions were predictive of progressive renal disease [32]. Also, low
mean arterial pressures (102 mm Hg) below the JNCV definition
of hypertension were predictive of a slower progression. This may
be analogous to the Framingham data that found no lower
threshold for blood pressure in terms of risk of stroke, the risk
simply being proportional to the blood pressure level from the
lowest to the highest recorded [33]. Also from the Framingham
study, a mean arterial pressure increase of 7.5 mm Hg was
associated with a 46% increase in the risk of stroke, a difference
similar to the 7 mm Hg difference seen between stable patients
and progressors in our trial. Since relatively high baseline mean
arterial pressures were predictive of a worse outcome, redefining
blood pressure goals in patients with IDDM and established renal
disease is necessary.
Peripheral edema and an increased urinary protein excretion
were predictors of a greater risk of doubling serum creatinine. It
is likely that sufficient protein losses in the urine lead to peripheral
edema and account for edema's strong predictive value. There has
been evidence to suggest that the degree of proteinuria is a
Table 2. Risk of nephropathy progression for baseline demographic
and clinical characteristics identified by a multivariate proportional
hazards regression analysis
Relative risk
(95% confidence interval)
Table 3. Baseline laboratory characteristics predictive of nephropathy
progression during a median follow-up of three years (range 1.8 to 4.8)
Characteristics
Doubling of serum creatinine
No P value
341
53.4 0.0 16
Data are based on 407 patients having a total of 68 doubling of serum
creatinine events with simultaneous adjustment for the demographic and
clinical characteristics listed as well as treatment group assignment
(Captopril or placebo).
40.3 5.70 <0.001
11.5 2.58 0.048
1.19 0.37
3.79 0.51
229 63.4
218 128
5.33 1.59
<0.001
<0.001
<0.001
0.030
<0.001
2.34 2.09 <0.001
11.2 5.15 0.007
86.3 41.3 <0.001
82.1 32.2 <0.001
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Hematocrit (4%)
Glycosylated HGB (2%)
Serum:
Creatinine (0.25 mg/dI)
Captopril
Placebo
Albumin (0.25 gidI)
Cholesterol (50 mg/dl)
Glucose (5—fold mg/dl)
Uric acid (1 mg/dl)
24 hour urine:
Total protein (5—fold g/day)
Urea nitrogen (3 g/day)
Renal clearance:
24 hour creatinine
(20 mI/mm/i .73 m2)
4-Period iothalamate
(20 mI/mm/i .73 m2)
Fig. 2. Risk of nephropathy progression for each
baseline laboratoty characteristics corrected for
treatment group assignment (Captopril or
placebo) based on proportional hazards regression
analysis. The relative risk (dot) and
corresponding 95% confidence interval
(horizontal line) associated with each baseline
risk factor (or specified increase) are plotted on
a natural logarithm scale. A dot to the left of
the vertical line suggests a reduction in the risk
of nephropathy progression for the index
characteristic, while a dot to the right indicates
an increased risk of progression. Because serum
creatinine interacted with treatment assignment,
relative risks were plotted for each treatment
group.
0.1 1.0 10
Table 4. Risk of nephropathy progression for baseline laboratory
characteristics identified by a multivariate proportional hazards
regression analysis
Relative risk
Baseline risk factor (95% confidence interval)
Relative risk
marker for worse progression and that decreasing proteinuria is a
marker for amelioration of disease processes [34, 35]. Although
the data analysis in this paper cannot comment on the potential
beneficial effects of decreasing proteinuria, the degree of baseline
proteinuria was a clear predictor of renal outcome. Proteinuria
confers a similar risk in non-diabetic renal disease [31].
Abnormalities in lipid metabolism frequently accompany renal
disease and may be important in the pathogenesis of renal injury.
Hypercholesteremia has been demonstrated to cause renal injury
in normal rats [36, 37] and altering lipid status has been demon-
strated to preserve renal function [38, 39]. While patients who
progressed more rapidly had higher cholesterol levels, this param-
eter did not prove to be an independent predictor. It is unknown
whether lowering the cholesterol in these patients would help slow
the rate of decline of renal function. Higher blood sugars at
baseline were associated with worse renal outcomes. Animal
models of diabetes and epidemiologic studies have implicated
hyperglycemia in the pathogenesis of long-term complications of
diabetes including the development of renal disease [40—42].
More recently, the Diabetes Control and Complications Trial has
demonstrated that intensive insulin therapy delays the onset and
slows the progression of diabetic retinopathy [43]. Thus, it is not
surprising that baseline blood glucose control would predict renal
outcomes in this study.
The entry level of serum ereatinine strongly predicted the rate
of renal progression as it does in other entities such as lupus
nephritis [44]. It is of particular interest that the enhanced risk was
0.38 (0.23 to 0.65)
0.73 (0.60 to 0.88)
1.63 (1.05 to 2.52)
Serum albumina
Assigned to Captopril treatment
Blood
Hematocrit (per increase
of 4%)
Serum
Glucose (per 5-fold increase
in mgjdl)
Crcatininc (per increase of
0.25 mg/dl)
24-Hour urine
Total protein (per 5-fold
increase in g/day)
3.0 g/dl 4.0 g/d
1.28 (1.04 to 1.58) 1.79 (1.45 to 2.20)
2.00 (1.25 to 3.20)
Based on 407 participants having a total of 67 doubling of serum
creatinine events with simultaneous adjustment for the laboratory vari-
ables listed as well as treatment group assignment (Captopril or placebo).
a Because serum creatinine interacted with serum albumin (P 0.009),
relative risks were calculated for two values of serum albumin.
particularly marked in subjects with normal albumin. Since there
was a strong interaction between these two variables the analysis
was performed at two different levels of albumin. Finally, it must
be pointed out that in the original analysis of the benefits of
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Captopril [16], a 48% risk reduction was noted. In the present
multivariate analysis, when adjusted for the laboratory measure-
ments that independently predicted progression, assignment to
Captopril had an even greater risk reduction (62%).
In summary, we conclude that a variety of important baseline
demographic, clinical and laboratory characteristics help identify
a subpopulation of patients with IDDM and established nephrop-
athy who have a marked increase risk of renal disease progression
during a median follow-up of three years. These patients should
probably be targeted for early aggressive interventions.
Reprint requests to Dr. Tomas Ben, C281, University of Colorado School
of Medicine, 4200 E. 9th Ave., Denver, Colorado 80262, USA.
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